The therapeutic potential of targeting MMP9, SPARC, and ITGA5 is heightened when considered in combination, as they are involved in different but complementary pathways of ECM remodelling, fibrosis, and tumor progression. This evidence concerns the gene ITGA5 and neoplasm.